Abstract
Introduction
Turmeric (the common name for Curcuma longa) is an Indian spice that belongs to the ginger family 1 . In ancient times, turmeric powder was utilised as a traditional and natural remedy for various health conditions, such as joint pain, ulcers, liver disease, wounds and skin diseases 2 . The active ingredient of turmeric is curcumin with chemical name diferuloylmethane 3 . Curcumin exhibits anti-microbial, anti-inflammatory, anti-oxidant and anti-neoplastic properties 4 , and has been extensively investigated for its proposed benefits in managing chronic inflammatory conditions. In inflammatory bowel disease (IBD), curcumin is proposed as an attractive alternative therapy to the conventional medicines 5, 6 . Curcumin is considered to be safe and inexpensive 7 and emerging evidence from pre-clinical studies indicates the potential benefits of curcumin supplementation in IBD [8] [9] [10] [11] . Clinical trials of curcumin have included a pilot study involving 5 patients with chronic ulcerative proctitis and 5 patients with Crohn's disease (CD) 12 . Curcumin was administered for 2 months to patients with proctitis and for 3 months to the patients with CD.All patients with proctitis experienced symptom relief, which was consistent with a significant reduction in inflammatory indices; in addition, four out of five patients were able to reduce concomitant medications. Four of the CD patients who completed the study showed a significant drop in disease activity and erythrocyte sedimentation rate. Further, in a randomzsed, double-blind, multicentre trial involving 89 patients with quiescent ulcerative coliti), 45 patients received curcumin plus sulphasalazine or mesalamine, and 44 patients received placebo plus sulphasalazine or mesalamine for 6 months 13 . At the completion of the study, relapse rates were 4.65% in the curcumin-treated group compared to 20.51% in the placebo group. These preliminary studies appear promising and suggest that curcumin co-administration with conventional medications may be a viable therapeutic approach. In addition to these human trials, promising results are also observed when curcumin is administered in experimental murine colitis models of IBD 9, 10, [14] [15] [16] [17] [18] . In these studies, curcumin-treated mice exhibited symptomatic relief, improved survival rates and decreased inflammatory indices. Addition of curcumin to mice diets resulted in a significant amelioration in the histological intestinal injury seen in the inflamed mucosa and lower mucosal cytokine levels
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. However, the role of curcumin in the management of active inflammation is less clear. The aim of this study was to investigate whether timing of exposure to curcumin and/or curcumin concentration influenced the inflammatory response in an in vitro model of intestinal inflammation. . Absorbance readings were then converted to picograms per millilitre based on standard curves obtained with the recombinant cytokine (lower detection limit of assay was 31.5 pg/ml).
Western blot analysis of IκB
HT-29 cells were seeded in a 6-well plate at a concentration of 10 6 cells per well and grown for 5 days before experiments. For some experiments, cells were treated with 50 µM curcumin for 1 hour before or at the same time during the administration of 100 ng/ml TNF-α. Cells were then incubated with TNF-α for 5, 15 and 30 minutes. Proteins were extracted from cells using radioimmunoprecipitation assay buffer (150 mM sodium chloride, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 50 mM Tris, pH 8.0) containing 10 mM NaF and a mixture of protease inhibitors (2 µg/ml Aprotinin, 10 µg/ml Leupeptin and 1 µg/ml Pepstatin A). Cell lysates were centrifuged at 12,000 g for 10 minutes, and supernatants were collected. The total protein concentration of the cell lysates was measured by the bicinchoninic acid method (Micro BCA protein assay reagent kit; Pierce Biotechnology-ThermoFischer Scientific). Equal amount of protein (40 µg) for all samples was loaded and run onto Tris-Glycine NB of 1 mL of cells in suspension was transferred to a separate tube and centrifuged at 1200g for 5 minutes. Supernatant was discarded and the pellet containing the cells was resuspended in warm media gently. Equal volumes of cells (25 µl) and trypan blue (Sigma-Aldrich) (25 µl) were mixed and cell viability counts were conducted using a haemocytometer and a light microscope. The viability was expressed as the percentage of unstained cells (viable) among the total cells.
Assessment of cell viability by MTT colourimetric assay kits
The assay was conducted according to the manufacture's instructions (Sigma-Aldrich). In brief, after 24 hours of incubation with curcumin, culture media was replaced with 1 ml per well phenol red-free McCoy´s 5A media (Banksia Scientific Company, QLD, Australia). One hundred microlitres of MTT (3-[4,5-Dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide; Thiazolyl blue) solution (5 mg/ml) was added to each well of cells and incubated further for 4 hours at 37°C with 5% CO 2 . In metabolically active cells, the MTT was converted to an insoluble purple formazan by cleavage of the tetrazolium ring by mitochondrial dehydrogenase enzymes. Following the incubation, the dye was solubilised in DMSO and 200 µl of the mixture was transferred to a well of a 96-well plate. Well absorbance was read at a wavelength of 570 nM by a Micro-plate reader (Bio-Rad, NSW, Australia). The amount of converted dye, representing metabolic activity, was determined by comparing to a standard curve.
Enzyme-linked immunosorbent assay to measure interleukin-8
The concentration of interleukin (IL)-8 in culture supernatant was measured using an enzyme-linked immunosorbent assay (ELISA) kit, according to manufacturer's protocol
Materials and Methods
The protocol of this study has been approved by the relevant ethical committee related to our institution in which it was performed. 
Cell culture and induction of

Results
Curcumin reduces epithelial cell viability at high concentrations HT-29 and INT407 cells were treated with increasing concentrations of curcumin (0, 10, 25, 50, 75 or 100 µM) in DMSO for 24 hours with cell viability measured. Additional DMSO only controls (cells exposed to 50 ng/ml TNF-α and DMSO without curcumin) were included. The final concentration of DMSO for all experiments remained constant at 0.1% v/v, which did not have an effect on cell viability ( Figure 1 ). Increasing concentrations of curcumin, (up to 50 µM) had no significant effect on cell viability, with viability remaining above 90% for both the cell lines (p > 0.05) (Figure 1 ). However, curcumin concentrations of 75 µM and above significantly decreased cell viability (p < 0.05 for both 75 and 100 µM curcumin) (Figure 1 ). Cell viability results were further supported by the MTT assay experiments that measured the mitochondrial dehydrogenase enzyme activity of the viable cells. HT-29 cells were treated with increasing concentrations of curcumin dissolved in DMSO (0, 10, 25, 50, 60, 75 and 100 µM) for 24 hours with cell activity measured. The final concentration of DMSO for all experiments including 0 µM curcumin treatment group (DMSOcontrol group) remained constant at 0.1% v/v. Curcumin, up to 50 µM concentrations, showed an increase in the mitochondrial dehydrogenase enzyme activity, while those treated with 60 µM or higher concentration of curcumin exhibited a significant drop in the activity as compared to the control group (p < 0.05 for 60, 75 and 100 µM treated groups) (Figure 2) . Therefore, for further experimentation, curcumin concentrations of up to 50 µM were used.
Curcumin inhibits IL-8 production from TNF-α-exposed HT-29 and
INT407 cells
Curcumin exhibited a strong antiinflammatory effect in response to TNF-α exposure of intestinal epithelial cells. In HT-29 cells, curcumin at low concentration (10 µM) in all the indicated pre-incubation time points (24, 6, 1 and 0 h) had no significant effection ameliorating IL-8 production from the cultured cells (p > 0.05 in all treated groups vs positive control group) ( Figure 3A) . However, at higher concentrations (25 and 50 µM), curcumin did significantly attenuatd IL-8 levels in a dosedependent fashion. Cell exposed to 25 µM curcumin showed significant reductions in IL-8 levels compared to the positive control (p < 0.01) ( Figure 3B ). Interestingly, IL-8 levels were not significantly different between cells with varying curcumin pre-incubation time (p > 0.05 for all comparisons at 24, 6, 1, and 0 hours) ( Figure 3B ), but by increasing curcumin concentration to 50 µM, the strongest anti-inflammatory response was observed with maximal reduction in IL-8 levels (p < 0. Competing interests: none declared. Conflict of interests: none declared.
All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript. All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.
each time point following TNF-α exposure, which was consistent with less phosphorylated IκB detected ( Figure 5 ). There was no difference in the IκB response whether or not cells were pre-incubated with curcumin prior to TNF-α exposure.
Discussion
These in vitro investigations have demonstrated that curcumin can prevent TNF-α-mediated production of IL-8 in human intestinal epithelial cells. Further, inhibition of IL-8 was comparable whether cells were pre-incubation with curcumin or if cells were exposed to curcumin at the same time as TNF-α administration. These results also indicatd that curcumin impaired the degradation of IκB and thereby modulated the nuclear factor (NF)-κB signal transduction pathway.
In numerous experimental murine models of colitis, there is evidence that curcumin has potential therapeutic and preventive benefits that may be applicable in the treatment of IBD 8, 14, 19 . Previously, using the human intestinal cell line (HCT116, HT-29 and CaCO 2 ), it was shown that curcumin pretreatment inhibited and modulated gene expression of IL-8 in response to inflammatory cytokine exposure 20, 21 . However, it was not investigated whether curcumin had a similar effect if given simultaneously with inflammatory inducers. The results presented in this paper indicate that curcumin pre-incubation had no measureable additional benefit compared to when curcumin was given with the inflammatory stimulus. However, curcumin concentrations did significantly affect IL-8 suppression. This finding indicates that curcumin concentration, bud not the timing of supplementation, likely determines the efficacy of curcumin in reducing inflammation.
Curcumin inhibits the activity of cyclooxygenase, lipoxygenase and inducible nitric oxide synthetase enzymes; thereby reducing pro-inflammatory cytokine production and the curcumin concentration dose did affect IL-8 level ( Figure 4D ). DMSO alone at 0.1% v/v had no measurable effect on IL-8 production in either of the two cells lines (Figures 3 and 4) .
Curcumin therapy suppresses IκB degradation in intestinal epithelial cells
There is a rapid degradation of IκB when HT-29 cells are exposed to TNF-α. IκB is detectable by Western blot in unstimulated cells, but is undetectable 5 and 15 minutes following TNF-α exposure ( Figure 5 ). IκB can be detected again 30 minutes after TNF-α exposure ( Figure 5 ). These observations are consistent with the appearance of phosphorylated IκB at 5 minutes following TNF-α exposure, which indicates that IκB is being phosphorylated and subsequently degraded by the proteasome activity ( Figure 5 ). In cells exposed to curcumin, IκB can still be detected at Figure 3C ). Moreover, again timing of curcumin pre-incubation did not alter the anti-inflammatory response for cells exposed to 50 µM curcumin (p > 0.05 for all comparisons; Figure  3C ). The dose-dependent curcumin response is clearly seen with no preincubation, where increase in the concentration of given curcumin results in further reduction in IL-8 level ( Figure 3D) .
In INT407 cells, low concentrations of curcumin (10 and 25 µM) had no suppressing effect on IL-8 production; conversely, there was a rise in the IL-8 levels ( Figures  4A and 4B) . However, curcumin of 50 µM significantly reduced IL-8 production in response to inflammatory stimulus (p < 0.001 for all comparisons compared to positive control; Figure 4C ). Like in HT-29 cells, timing of curcumin exposure dose did not influence this response (p > 0.05 for all comparisons; Figure 4C ), but Competing interests: none declared. Conflict of interests: none declared.
All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript. All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.
indicated that curcumin inhibits IκB degradation whether given prior to or at the same time as an inflammation inducer. This suggests that curcumin gains rapid entry into the cells and become active and does not need to be metabolised to be activated.
It is important to note that, according to these experiments curcumin may have a narrow safe window. Cells treated with curcumin consentration greater than 50 µM had a significant drop in cell viability that was consistent with the reduction in the mitochondrial dehydrogenase enzyme activity. In contrast clinical trial has reported that patients were able to tolerate up to 8g of curcumin daily for 3 months wih no reported toxicity 33 . This apparent discrepancy is likely due te poor pharmacokinetic properties of curcumin, including very low bioavailabilit, poor absorption and rapid metabolic elimination 34 when curcumin is delivered in the absence of a vehicle. Another study has found that the highest achieved peak serum concentration of curcumin in the peripheral blood was only 139 nM measured 4 hours after a single oral dose of 12 g curcumin 35 . Further, limited transepithelial flux and rapid metabolism in the gut epithelium are likely to impair curcumin exerting its beneficial effect locally on gut epithelium 36 . In our in vitro experiments, curcumin was delivered via DMSO, which would enhance delivery to the cell cytoplasm. Thus, this may explain why curcumin has shown better outcomes in both in vitro and ex-vivo settings than in clinical trials and may also explain the lack of toxicity despite high doses. Therefore, to improve clinical outcomes and to fully utiizse the properties of this agent, future clinical application of curcumin may benefit from further investigation of curcumin solubility and targetd delivery of curcumin to the gut. However, improving delivery in vivo must also be done cautiously and with concurrent investigation of cell toxicity.
Thus, activity of the NF-κB pathway is determined by the state of the IκB protein. In this papere we report that a phosphorylated IκB band was evident shortly after the addition of TNF-α, which was consistent with the initial drop in IκB. Curcumin, with or without pre-incubation, appeared to prevent the rapid and initial loss of IκB. The lack of IκB degradation in curcumin-treated cells indicates inhibition of NF-κB signal transductione A previous report involving an intestinal epithelial cell line indicated that curcumin treatment blocks IL-8 expression through inhibition of NF-κB pathway 21 . Of interest, in that study, curcumin was pre-incubated with cells prior to exposure to inflammatory mediators. However, in the present study results have down-regulating mitogen activated and Janus kinases [22] [23] [24] . These effects are primarily a result of influencing the NF-κB signal transduction pathway 21, [25] [26] [27] . The NF-κB/Rel family of transcription factors plays a role in regulating the expression of a large number of genes, particularly those determining immune functions and acute-phase reactions 28 . Inhibition of NF-κB is of particular importance and is considered a putative target for intervention in IBD 29, 30 . In unstimulated cells, most of the Rel/NF-κB factors are sequestered in the cytoplasm as inactive complexes bh associatinn with a group of inhibitory proteins (IκB) 31 . Once phosphorylated, Iκl dissociates from the NF-κB complex and permits the subsequent translocation of NF-κB to the nucleus These cell lines provide an approximation of the human gut epithelial surface, but may not precisely reflect normal human intestinal physiology in vivo. However, due to their critical role in the gut mucosal immune response 37 , epithelial cell lines are very often used as an in vitro model to reflect in vivo event [38] [39] [40] [41] [42] . Intestinal epithelial cells act as a protective barrier against different invasive infectious agents, toxins and antigenic factors within the gut lumen 43, 44 , and are also in contact with cytokines secreted by other cells in the intestinal mucosa 45 . In addition, intestinal epithelial cells secrete numerous cytokines involved in intestinal injury and damage [46] [47] [48] . Thus, the in vitro results presented here can be of value when contemplating in vivo curcumin supplementation.
Conclusion
In summary, curcumin prevented and ameliorated TNF-α-induced inflammation in two intestinal cell lines. This action was mediated through inhibition of IκB degradation, and therefore the NF-κB signal transduction pathway is also blocked in a similar way as with or without pre-incubation. This study further adds support that curcumin has the potential to improve intestinal diseases associated with inflammation such as IBD. This study suggests that curcumin does not likely need to be metabolised and is active in its natural state. Therefore, curcumin supplementation may be useful to both prevent inflammatory relapse episodes and treat current inflammatory flare. However, curcumin concentration and delivery method are likely to be essential for the successful therapeutic utilisation of curcumin, and definitive clinical studies
